Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
September 10 2024 - 4:05PM
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage
biotechnology company whose mission is to develop effective, safe,
and accessible cell therapies for patients with devastating
autoimmune diseases and cancers, today announced that management
will participate in a fireside chat at the 2024 Cantor Fitzgerald
Global Healthcare Conference on Wednesday, September 18, 2024, at
8:00 a.m. ET / 5:00 a.m. PT, in New York City, New York.
Members of the Artiva management team will also be available to
participate in in-person investor meetings with investors who are
registered to attend the conference.
Investors and the general public are invited to listen to a live
webcast of the fireside chat through the "Investors" section
on Artivabio.com. A webcast replay will be made available
following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission
is to develop effective, safe and accessible cell therapies for
patients with devastating autoimmune diseases and cancers. Artiva’s
lead program, AlloNK®, is an allogeneic, off-the-shelf,
non-genetically modified, cryopreserved NK cell therapy candidate
designed to enhance the antibody-dependent cellular cytotoxicity
effect of monoclonal antibodies to drive B-cell depletion. AlloNK®
is currently in clinical trials for treatment of systemic lupus
erythematosus, for patients with or without lupus nephritis, and in
an investigator-initiated basket trial in multiple autoimmune
indications. Artiva’s pipeline also includes CAR-NK candidates
targeting both solid and hematologic cancers. Artiva was founded in
2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a
leading healthcare company in the Republic of Korea, pursuant to a
strategic partnership granting Artiva exclusive worldwide rights
(excluding Asia, Australia and New Zealand) to GC Cell’s NK cell
manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more
information, please visit https://www.artivabio.com/.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this press release that are not statements of historical fact are
forward-looking statements. Such forward-looking statements
include, without limitation, statements regarding upcoming events
or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at
such events. These forward-looking statements are based on
the beliefs of the management of the Company as well as assumptions
made by and information currently available to the Company. Such
statements reflect the current views of the Company with respect to
future events and are subject to known and unknown risks and
uncertainties. In light of these risks and uncertainties, the
events or circumstances referred to in the forward-looking
statements may not occur. These and other factors that may cause
the Company’s actual results to differ from current expectations
are discussed in the Company’s filings with the Securities and
Exchange Commission (the “SEC”), including the section titled “Risk
Factors” in the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2024. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date this press release is given. Except as required
by law, the Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsInvestors: Neha
Krishnamohan, Artiva
Biotherapeutics, ir@artivabio.comMedia: Jessica Yingling,
Ph.D., Little Dog Communications
Inc., jessica@litldog.com, +1.858.344.8091
Artiva Biotherapeutics (NASDAQ:ARTV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Artiva Biotherapeutics (NASDAQ:ARTV)
Historical Stock Chart
From Sep 2023 to Sep 2024